4th Quarter - Report

CROHN'S & COLITIS FOUNDATION for CROHN'S & COLITIS FOUNDATION

Firm
Client
Income
—
Expenses
$50,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

Increasing access to care by limiting step therapy. Safe Step Act HR 2630, S 652. Lowering out-of-pocket costs for patients. HELP Copays Act HR830, S1375 HHS response to HIV+Hep vs Baccerra law suit. FY 2026 HHS Notice of Benefit Payments and Parameters, copay assistance. Pharmacy Benefit Manager Reform. PBM Transparency Act S 127; Prescription Pricing for the People Act S 113; PBM Reform Act, S. 1339; Hidden Fee Disclosure Act HR 4508. Funding for medical research and education at the NIH and CDC. Biosimliar interchageability. HHS rule on Section 1557 of the Affordable Care Act (ACA) that will strengthen non-discrimination protections in health care. Fifth Circuits decision in Alliance for Hippocratic Medicine et al. v FDA et al. Committee on Education and Workforce ERISA RFI: step therapy reform, copay accumulators and maximizers. FDA - proposed guidance on Diversity Action Plans for medical clinical trials; proposed guidance on development of medications for pediatric inflamatory bowel disease patients.

LobbyistCovered position, as disclosed
ERIN HENNESSEY MCKEON —

Contacted: Natl Institutes of Health (NIH); Justice, Dept of (DOJ); Food & Drug Administration (FDA); SENATE; HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS)

Bills named: H.R. 2630 (118th), H.R. 830 (118th), S. 1339 (118th), H.R. 4508 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.